激活转录因子
ATF3
转录因子
生物
分子生物学
收缩性
CTCF公司
ATF4
压力过载
心力衰竭
基因表达
内科学
内分泌学
医学
发起人
基因
增强子
生物化学
心肌肥大
作者
Heng Lin,Hsiao-Fen Li,Hsi-Hsien Chen,Pei‐Fang Lai,Shu‐Hui Juan,Jin‐Jer Chen,Ching‐Feng Cheng
出处
期刊:Molecular Pharmacology
[American Society for Pharmacology and Experimental Therapeutics]
日期:2014-02-18
卷期号:85 (5): 682-691
被引量:51
标识
DOI:10.1124/mol.113.090092
摘要
Activating transcription factor 3 (ATF3), a cAMP response element-binding protein/ATF family transcription factors member, has been implicated in the cardiovascular and inflammatory system and is rapidly induced by ischemic-reperfusion injuries. We performed transverse aortic banding (TAB) experiments using ATF3 gene-deleted mice (ATF3−/−) and wild-type (WT) mice to determine what effect it might have on heart failure induced by pressure overloading. Compared with the WT mice, ATF3−/− mice were found by echocardiography to have decreased left ventricular contractility with loss of normal cardiac hypertrophic remodeling. The ATF3−/− mice had greater numbers of terminal deoxynucleotidyl transferase–mediated digoxigenin-deoxyuridine nick-end labeling–positive cells and higher levels of activated caspase-3, as well as more apoptosis. Restoration of ATF3 expression in the heart of ATF3−/− mice by adenovirus-induced ATF3 treatment significantly improved cardiac contractility after TAB. The results from molecular and biochemical analyses, including chromatin immune-precipitation and in vitro /in vivo promoter assays, showed that ATF3 bound to the ATF/cAMP response element of the Beclin-1 promoter and that ATF3 reduced autophagy via suppression of the Beclin-1–dependent pathway. Furthermore, infusion of tert-butylhydroquinone (tBHQ), a selective ATF3 inducer, increased the expression of ATF3 via the nuclear factor erythroid 2–related transcriptional factor, inhibited TAB-induced cardiac dilatation, and increased left ventricular contractility, thereby rescuing heart failure. Our study identified a new epigenetic regulation mediated by the stress-inducible gene ATF3 on TAB-induced cardiac dysfunction. These findings suggest that the ATF3 activator tBHQ may have therapeutic potential for the treatment of pressure-overload heart failure induced by chronic hypertension or other pressure overload mechanisms.
科研通智能强力驱动
Strongly Powered by AbleSci AI